Key points
Started in 2008, HPV-IMPACT monitors rates of high-grade cervical lesions in the United States. Scientists use data from the project to determine the impact of the U.S. HPV vaccination program on cervical precancers caused by HPV.
Data Highlights
HPV-IMPACT has enabled CDC to describe trends in the cervical lesions that could progress to cancer and the reduction of cancer-causing HPV types (such as HPV16 and HPV18) in these cervical lesions.
- From 2008 to 2016, in 20- to 24-year-olds, there were significant reductions in new cervical precancers caused by vaccine-preventable HPV types 16 and 18. There was also a reduction in precancers caused by HPV type 31, a high-risk HPV type not targeted by vaccination, suggesting cross-protection.
- Compared to 2008-2009, cervical precancer rates in 2014-2015 were 50% lower in 18- to 20-year-olds and 36% lower in 21- to 24-year-olds.
- By 2014, the percentage of cervical lesions due to types that are prevented by the HPV vaccine had dropped by 40% among those vaccinated.
- HPV-IMPACT data were used for the first national estimate of CIN2+ cases. We estimated that 196,000 CIN2+ cases were diagnosed in the United States. In 2016, 36% of which were in 18- to 29-year-olds.